Oxytocin intranasal - Trigemina

Drug Profile

Oxytocin intranasal - Trigemina

Alternative Names: TI-001; TI-114

Latest Information Update: 31 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trigemina
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Migraine
  • No development reported Headache; Trigeminal neuralgia

Most Recent Events

  • 29 Mar 2016 Trigemina completes a phase-II trial in Migraine in Australia, Chile and New Zealand (Intranasal)(NCT01839149) before December 2015
  • 15 Mar 2016 Biomarkers information updated
  • 11 Aug 2015 Trigemina has patent protection for TI 114 in USA and other countries around world (Trigemina website, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top